1 Temporal multi-omic analysis of COVID-19 in end-stage kidney disease

- 2
- 3 Emily Stephenson^{1,2*}, Erin Macdonald-Dunlop^{3*}, Lisa M Dratva^{2,4,5*}, Rik G.H. Lindeboom²,

4 Zewen Kelvin Tuong^{4,6}, Win Min Tun¹, Norzawani B Buang³, Stephane Ballereau², Mia

- 5 Cabantaus^{4,6}, Ana Peñalver^{4,6}, Elena Prigmore², John R Ferdinand^{4,6}, Benjamin J Stewart^{2,4,6},
- 6 Jack Gisby³, Talat Malik³, Candice L Clarke³, Nicholas Medjeral-Thomas³, Maria Prendecki³,
- 7 Stephen McAdoo³, Anais Portet^{4,6}, Michelle Willicombe^{3,7}, Eleanor Sandhu^{3,7}, Matthew C.
- 8 Pickering³, Marina Botto³, Sarah A. Teichmann^{2,5,4#}, Muzlifah Haniffa^{2,1,8#}, Menna R.
- 9 Clatworthy^{4,6,2#}, David C. Thomas^{3,4#}, James E. Peters^{3#}

10 Affiliations

- 11¹ Biosciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
- 12 ² Cellular Genetics, Wellcome Sanger Institute, Hinxton, United Kingdom
- ³ Department of Immunology and Inflammation, Imperial College London, London, United
 Kingdom
- ⁴ Department of Medicine, University of Cambridge, Cambridge, United Kingdom
- ⁵ Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge,
- 17 United Kingdom,
- 18 ⁶ Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of
- 19 Cambridge, Cambridge, United Kingdom
- 20 ⁷ Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust,
- 21 Hammersmith Hospital, London, United Kingdom
- 22 ⁸ Department of Dermatology and NIHR Newcastle Biomedical Research Centre, Newcastle
- 23 Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
- 24 *Equal contribution
- 25 [#]Senior authors
- 26 Correspondence to j.peters@imperial.ac.uk

27 Summary

28

29 Patients with end-stage kidney disease (ESKD) are at high risk of severe COVID-19. We 30 performed longitudinal single cell multi-omic immune profiling of ESKD patients with COVID-31 19, sampled during two waves of the pandemic. Uniquely, for a subset of patients, we obtained 32 samples before and during acute infection, allowing intra-individual comparison. Using single-33 cell transcriptome, surface proteome and immunoreceptor sequencing of 580,040 high-quality 34 cells, derived from 187 longitudinal samples from 61 patients, we demonstrate widespread 35 changes following infection. We identified gene expression signatures of severity, with the 36 majority of pathways differentiating mild from severe disease in B cells and monocytes. For 37 example, gene expression of PLAC8, a receptor known to modulate SARS-CoV-2 entry to 38 cells, was a marker of severity in CD14+ monocytes. Longitudinal profiling demonstrated 39 distinct temporal molecular trajectories in severe versus mild disease, including type 1 and 40 type 2 interferon signalling, MHC gene expression and, in B cells, a proliferative signature

- 41 (*KRAS* and *MYC*). Evaluation of clonal T cell dynamics showed that the fastest expanding
- 42 clones were significantly enriched in known SARS-CoV-2 specific sequences and shared
- 43 across multiple patients. Our analyses revealed novel TCR clones likely reactive to SARS-
- 44 CoV-2. Finally, we identified a population of transcriptionally distinct monocytes that emerged
- 45 incretipheraliblood following glucocordice id treatments overall, coundated the temporal

46 dynamics of the immune response in COVID-19 in a high-risk population and provide a47 valuable open-access resource.

48

49 Introduction

50

51 COVID-19, caused by the SARS-CoV-2 virus, displays marked clinical heterogeneity, varying 52 from minimal symptoms to fatal disease. This variation in outcome is not random; severe or 53 fatal COVID-19 disproportionately affects certain strata of the population. Demographic risk 54 factors for severe COVID-19 include older age, male sex, and non-white ethnicity. Underlying 55 medical conditions also impact the risk of severe COVID-19. End-stage kidney disease 56 (ESKD) is one of the strongest risk factors for severe COVID-19, with a UK population-scale study estimating a hazard ratio for death of 3.69¹. While vaccines have been highly effective 57 58 in reducing morbidity and mortality from SARS-CoV-2, novel viral variants of concern (VoC) 59 continue to emerge and ESKD patients remain at elevated risk of hospitalisation and death. 60 There is, therefore, a need for research and therapeutic efforts focusing on ESKD patients 61 and other high-risk groups.

62

63 A central feature of the pathophysiology of severe COVID-19 is an excessive host inflammatory response leading to tissue injury. Autopsies revealed an accumulation of 64 65 activated immune cells but little or no active virus². Severe disease is characterised by excess circulating monocytes, neutrophils and myeloid progenitors and elevated pro-inflammatory 66 67 cytokines and chemokines, which contribute to endothelial damage and the formation of 68 microthrombi. The importance of the host immune response is further underscored by the 69 efficacy of therapies targeting inflammation. Glucocorticoids, which have pleiotropic effects on 70 inflammatory pathways, and targeted inhibition of the IL6 signalling pathway, both reduce 71 mortality in COVID-19^{3,4,5}. Drugs targeting the JAK-STAT pathway also appear promising⁶. 72

73 ESKD is defined as irreversible loss of renal function with a glomerular filtration rate <15 74 mls/min/1.73m² and is fatal without dialysis or transplantation. In addition to loss of glomerular 75 filtration, ESKD is a systemic disease associated with profound changes in hormonal, 76 cardiovascular and haematopoietic function⁷. Such disturbances of normal physiology are also 77 associated with changes in immune function, and ESKD patients have both increased 78 susceptibility to infection and impaired vaccination responses⁸. Conversely, despite evidence 79 of impaired specific adaptive immune responses, ESKD is also characterised by a chronic pro-80 inflammatory state⁷.

81

82 Thus, patients with ESKD may be at high risk of complications of SARS-CoV-2 due to their 83 preponderance of cardiometabolic risk factors, as well as both impaired immunity and pro-84 inflammatory state secondary to uraemia. An outstanding question is whether patients with 85 ESKD mount a qualitatively different immune response to SARS-CoV-2 that drives their 86 susceptibility to severe COVID-19. Furthermore, the need to attend medical facilities for 87 regular haemodialysis, regardless of infection with SARS-CoV-2, provides a unique 88 opportunity to evaluate the temporal dynamics of the host immune response through serial 89 sample collection in both the inpatient and outpatient setting.

90

Here, we longitudinally profile the evolving immune cellular landscape driven by COVID-19
infection in ESKD patients, allowing us to produce single-cell resolution multi-omic temporal
trajectories in the context of renal failure. Uniquely, we collected samples from the same set

94 of individuals before and during SARS-CoV-2 infection. Our data provide a rich resource for
95 examining the complex longitudinal dynamics of COVID-19 infection in the context of an
96 important and clinically vulnerable patient group.

- 98 Results
- 99

97

100 Longitudinal immune cell profiling in ESKD patients with COVID-19

101

102 To investigate the dynamics of the immune cellular landscape in ESKD patients with COVID-103 19, we performed longitudinal blood sampling and profiling of peripheral blood mononuclear cells (PBMC) in ESKD patients. Patients were recruited from a single centre in London, UK, 104 105 during two distinct waves of COVID-19. The first cohort ('2020 Cohort') (n=22) were recruited 106 in April-May 2020, during the initial phase of the pandemic and before the advent of 107 vaccination. This cohort consisted of COVID-19 positive ESKD patients, including both 108 inpatients and outpatients, with a spectrum of illness severity from mild to critical (Fig. 1A, 109 Supp. Table 1). Following COVID-19 diagnosis, serial blood sampling was performed over 110 the course of the illness (Fig 1B). In addition, we recruited COVID-19 negative ESKD patients 111 to provide an appropriate control group. This group was well-matched in terms of age, sex, 112 and ethnicity (Supp. Table 1).

113

The second cohort ('2021 Cohort') (n=16) consisted of ESKD patients with COVID-19, sampled between January-March 2021 (when the alpha variant was the predominant variant in the UK). These patients were recruited as part of the COVID-19 negative control group in the 2020 Cohort. Again, serial blood sampling was performed during the acute illness. Thus, for the 2021 Cohort we had matched samples from pre-infection and during acute COVID-19, enabling intra-individual analysis. In addition, for a subset of the 2021 Cohort we collected a convalescent sample approximately 2 months after infection (n=10). (**Fig. 1A-B**).

121

122 To provide a comprehensive yet granular assessment of cellular and molecular changes, we 123 used a single-cell multi-omic approach, performing Cellular Indexing of Transcriptomes and 124 Epitopes by sequencing (CITE-seq) of PBMC samples with matched T cell receptor 125 sequencing (TCR-seq) and B cell receptor sequencing (BCR-seq) (Fig. 1A, Supp. Table 2). 126 To exclude low quality cells, we removed those with less than 200 genes, more than 10% 127 mitochondrial reads and fewer than 1000 UMIs. We performed genotype-based 128 demultiplexing of pooled samples (Methods) and removed cells with genotypes not fully 129 resolvable. The full dataset consisted of 580,040 cells, representing 187 longitudinal samples 130 from 61 patients (median of 3 samples per patient).

131

For initial cell type annotation, we separated the data analyses into three broad categories of 132 133 cell types: i) B cells, ii) T cells and innate lymphocytes, and iii) myeloid and non-immune 134 hematopoietic cells (Fig. 1C). Data were integrated per patient to account for technical 135 artefacts (Methods). Using semi-automatic cell type annotations with CellTypist⁹, previously published COVID-19 reference atlases^{10,11}, and canonical marker genes, we were able to 136 137 identify 39 cell types (Fig. 1C, Supp. Fig. 1A-D). These comprised known subtypes of 138 monocytes (classical CD14+ mono, non-classical CD16+ mono and intermediate CD14+ CD16+ mono) and dendritic cells (DCs), plus sub-populations displaying an interferon-139 140 stimulated signature¹¹ and complement expressing CD16+ monocytes that we have described previously (Fig. 1C, Supp. Fig. 1B)¹⁰. Within the B cell compartment, we leveraged the 141

142 availability of paired single-cell BCR-seq and CITE-seq data to detect 9 sub-populations. (Fig. 143 1C, Supp. Fig. 1C). Similarly, using TCR-seg and CITE-seg data, we were able to recover 15

144 clusters encompassing T cells, natural killer (NK) cells and innate-like lymphocytes (ILC) (Fig. 145 1C, Supp. Fig. 1D).

146

147 Altered cellular and transcriptomic profiles in ESKD patients with COVID-19

148

149 To understand the changes in peripheral immune cellular proportions in COVID-19, we 150 compared samples from COVID-19 positive ESKD patients to those from COVID-19 negative ESKD patients. We first compared samples during the first week of COVID-19 (week 1) to 151 COVID-19 negative samples. Analysis using broad cell type annotations showed a significant 152 decrease in the relative abundance of the total monocyte population in COVID-19 positive 153 154 versus COVID-19 negative ESKD patients (Fig. 2A, Supp. Table 3). More granular cell-type 155 categorisation revealed that samples taken during week 1 from COVID-19 positive patients 156 had a significantly lower relative abundance of all monocyte subsets including classical (CD14 157 mono), non-classical (CD16 mono) and intermediate CD14+CD16+ (Int. mono) monocytes 158 (Fig. 2B-D, Supp. Table 3). Relative abundances of CD8+ memory T cells and CD4+ CTL 159 and DC3 were reduced while those of naive B cells increased (Fig. 2E-H, Supp. Table 3). There were no significant changes in cell abundance between samples taken in the second 160 161 week of COVID-19 compared to the first week.

162

Next, to assess immune cell transcriptomic changes in COVID-19 in ESKD patients, we 163 164 performed differential gene expression analysis within each cell type, comparing samples from 165 COVID-19 positive and COVID-19 negative patients (Supp. Table 4). To identify the biological 166 pathways implicated by these differentially expressed genes, we performed gene set 167 enrichment analysis (Supp. Table 5). We observed widespread transcriptomic changes between COVID-19 positive and negative samples across numerous cell types. In the 2020 168 169 Cohort, the most consistent finding was an enrichment of interferon alpha and beta response 170 pathways across a broad range of innate and adaptive immune cells (Fig. 2I, Supp. Table 5). 171

172 B cells exhibited the greatest number of significantly enriched pathway terms, totalling 240 173 pathways (Supp. Table 5). Many of these contain genes that are involved in the cell cycle and 174 DNA repair, likely reflecting the strong B cell proliferative response involved in initiating 175 adaptive immunity to SARS-CoV-2. Similarly, expression of genes relating to protein 176 translation and post-translational modification were up-regulated, likely relating to the 177 generation of an antibody response. Many of the enriched pathways were also noted in B cell 178 antibody-secreting cells (B-ASC). Examining other cell types, we identified 19 enriched 179 pathways in monocytes, 17 in NK cells, 15 in dendritic cells, 8 in CD4+ T cells, 7 in CD8+ T cells (Fig. 2I, Supp. Table 5). 180

181

182 Some pathways were significantly enriched between COVID-19 positive and COVID-19-183 negative ESKD samples across multiple cell types. For example, we observed a significant negative enrichment of the "Orexin Receptor Pathway" across multiple innate immune cell 184 types, including monocytes (adjusted P 2.36x10⁻⁵), dendritic cells (adjusted P 2.01x10⁻⁸), and 185 NK cells (adjusted P 0.014) (Supp. Table 5). The leading-edge subset of genes that 186 contributed to this term included SGK1, GADD45B, MAFF, PDP1, ICAM1, TENT5A, HIF1A, 187 188 TNF, ID3, CDKN1A, FOSB, HBEGF, NR4A3, VEGFA, BHLHE40, CXXC5, NOCT, IL1B, 189 CXCL2 and HSPA5 (Fig. 2J), many of which are cellular stress response genes. Analysis of

190 monocyte subsets using more fine-grained annotation, revealed enrichment of the pathway 191 specifically in classical CD14 monocytes, and not in intermediate and non-classical CD16 192 monocytes, suggesting the former was the source of the signal in monocytes. In the smaller 193 2021 Cohort, where we had paired pre-infection and infection samples from the same 194 individuals, we replicated the findings of significant enrichment of the "Orexin Receptor 195 Pathway" in CD14+ CD16- monocytes and NK cells, but not in dendritic cells (**Supp. Table** 196 **5**).

197

198 Overall, our findings comparing COVID-19 positive and negative samples from ESKD patients 199 are broadly similar to those described previously in other more general patient populations.

- 200
- 201 202

Immune cell transcriptomic correlates of COVID-19 severity in ESKD patients

We next assessed molecular and cellular changes associated with COVID-19 severity at the time of blood sampling, categorised as mild, moderate, severe, or critical (Methods). Analysis of cell type numbers comparing samples taken from patients at the time of severe or critical disease (hereafter 'severe/critical', n=56) to those taken at the time of mild or moderate disease (hereafter 'mild/moderate', n=84) revealed that the relative abundance of dividing B-ASC cells was increased in the severe/critical group (**Fig. 3A, Supp. Table 6**).

209

210 We then performed differential gene expression within each cell type, again comparing 211 samples taken at the time of severe/critical COVID-19 to mild/moderate COVID-19 (Supp. 212 Table 7). Taking genes significantly associated with disease severity, we identified the 213 corresponding biological pathways through enrichment analysis (Fig. 3B, Supp. Table 8). 214 Where significant enrichment of pathways was identified within a cell type, we then used a 215 more granular cell type annotation to delineate the source of the signal. We identified 86 216 pathways that differentiated mild/moderate from severe/critical disease. The majority of these 217 were in the B cell (35) or monocyte (29) compartment. 11 pathways were associated with 218 severity in NK cells and 5 in gamma delta cells with only 2 enriched pathways in CD4+ helper 219 T cells with none in CD8+ T cells. Similarly, at the single gene level, 205 genes distinguished 220 mild/moderate from severe/critical disease. 125 of these were in all monocytes or 221 CD14+CD16- classical monocytes and 21 were in B cell subsets (Supp. Table 8). 222

In B cells, "Antibody secreting cells" and "Antibody secreting cells that produce IgA", numerous pathways relating to cell division were enriched in severe/critical disease. This is likely to represent increased activation of the adaptive immune response in severe/critical disease and the initiation of a response to drive neutralising antibody production. In dividing antibody secreted cells (B_ASC_dividing) and switched memory B cells, increased interferon signalling pathways also distinguished severe/critical from mild/moderate disease (**Supp. Table 8**).

229

230 In monocytes, differential gene expression analysis between mild/moderate and severe/critical 231 samples revealed significant enrichment of numerous pathways, including the KEGG "Asthma" and "Graft Versus Host Disease", "Leishmania Infection" and "Allograft Rejection" 232 233 pathway terms (Supp. Table 8). Many genes in these pathways were downregulated in 234 severe/critical relative to mild/moderate disease and their high enrichment scores are driven, 235 in part, by the high representation of HLA genes in the pathways. This is likely to reflect the 236 downregulation of MHC molecules on antigen presenting cells in severe COVID-19 that has 237 been previously reported. We observed down-regulation of HLA-DPB1, HLA-DPA1, HLA-

238 DRB1, HLA-DRA and HLA-DQA1 in all monocytes (Fig. 3C). This was accompanied by downregulation of CD163 as noted in other studies. We also noted up-regulation of genes 239 240 previously associated with severity such as S100A8, S100A9, S100A12 and MCEMP1 (Fig. 241 **3C)**¹². In all monocyte subsets, the most differentially expressed gene between mild/moderate 242 and severe/critical samples was *TNF*, encoding TNF- α (p-value 6.4 x10⁻¹¹⁶) (Supp. Table 7). Unexpectedly, given its pro-inflammatory effects, TNF gene expression was lower in 243 244 severe/critical disease. We hypothesised that this might be as a result of negative feedback 245 from elevated TNF-a at the protein level. We therefore compared monocyte TNF gene 246 expression levels to protein levels of plasma TNF-g measured using Olink immunoassays in 247 the same set of samples. This revealed higher plasma TNF-q protein in samples taken at the time of severe/critical disease. Correlation analysis between plasma TNF-a protein monocyte 248 249 TNF gene expression revealed a weak negative correlation (Pearson r -0.15), demonstrating 250 an uncoupling of plasma protein and gene expression levels (Fig. 3D).

251

252 Given the importance of monocytes in the host immune contribution to COVID-19 severity¹³, 253 we performed a deeper analysis of specific subsets. In classical CD14+ monocytes, there was 254 enrichment for the Reactome "MHC Class II Antigen Presentation", KEGG "Type I Diabetes Mellitus" and "Graft Versus Host Disease" and Reactome "Interferon Gamma Signalling" in 255 256 severe disease (Supp. Table 8). Many of these pathway terms were driven by genes 257 encoding MHC class II molecules (Supp. Fig. 2A-F). Within CD14+ monocytes, there was also enrichment of the matrisome-associated pathway, including increased amphiregulin 258 (AREG) gene expression (Fig. 3E, Supp. Table 8). We and others have previously reported 259 AREG protein up-regulation in plasma in severe disease^{14,15}. The present study suggests that 260 261 CD14+ monocytes may contribute to this. The Reactome "Neutrophil Degranulation" module 262 was also enriched in CD14+ monocytes in severe disease (Supp. Table 8). PLAC8 is a 263 leading-edge gene in this pathway. In our dataset, it is significantly more highly expressed in severe disease (Fig. 3E, Supp. Table 7). PLAC8 over-expression makes cells, including 264 265 immune cells, permissive for SARS-CoV-2 infection, and thus high expression of this molecule 266 in patients with severe/critical disease may predispose them to worse outcomes¹⁶.

267 We also observed significant transcriptomic differences in NK cells between mild/moderate and severe/critical COVID-19. This included differential expression of genes relating to both 268 269 TLR4 and TLR9 signalling pathways as well as those in the 'Oncostatin M Pathway' (Supp. 270 Tables 7-8). We previously reported upregulation of plasma protein levels of Oncostatin M in 271 severe COVID-19¹⁴. This cytokine is known to regulate IL-6 and GM-CSF production, which 272 have been previously implicated as drivers of severe COVID-19¹⁷. In dendritic cells, the sole 273 pathway significantly associated with severity was the 'Orexin Receptor Pathway' which 274 displayed a negative enrichment score in severe disease (Supp. Table 8). This pathway was 275 not significantly associated with severity in any other cell type, in contrast to the COVID-19 276 positive versus COVID-19 negative ESKD patient analysis, where we observed significant 277 enrichment of this patient across multiple cell types.

278

In summary, mild/moderate and severe/critical disease were distinguished by transcriptional
changes in numerous cell subsets. These were dominated by signals from B cell and
monocyte subsets with a minor contribution from NK cells. By contrast, transcriptional changes
in conventional alpha beta T cells were less able to distinguish mild/moderate and
severe/critical disease.

284

286

285 **Temporal gene expression trajectories vary according to disease severity**

287 The host response to infection is a dynamic process involving both the innate and adaptive 288 immune systems. To understand these temporal dynamics in COVID-19, we performed 289 longitudinal analysis of our multi-omic data. Cell type composition analysis revealed that most 290 cell subtypes displaying an interferon-stimulated gene expression signature were significantly 291 increased within the first week following symptom onset, and then gradually reduced over time 292 (Fig. 4A). We observed significant increases in the relative abundance of some cell types 293 persisting into weeks 2 and 3 following symptom onset (switched memory B cells, CD14 and 294 CD16 monocytes, DC3, NK and CD8+ CTLs). I B cells, NK cells, CD4+ helper T cells, I CD8+ 295 T cells, cytotoxic CD8+ T cells and Tregs were enriched in recovery samples. More generally, 296 there was an increase in the relative abundance of adaptive immune cells over the course of 297 the infection. As expected from a viral airway infection, compositions of antibody secreting B 298 cells, predominantly of class-switched (IgG and IgA) antibody isotypes, were increased 299 already in the first week after onset of disease, persisting for up to three weeks. Relative 300 numbers of most CD4+ and CD8+ T cell subsets gradually decreased over time, with the 301 exception of cvcling CD4+ T cells (Fig. 4A).

302

303 We next assessed the temporal patterns of gene expression changes during COVID-19 in 304 ESKD patients and how these vary according to overall clinical course (defined by peak illness 305 severity, binarised as mild/moderate or severe/critical). To achieve this, we performed 306 longitudinal modelling using a linear mixed model with a time x peak severity interaction term. 307 To reduce dimensionality, we analysed genes grouped together as modules according to 308 pathway terms, using the Hallmark, Reactome and KEGG databases. A pathway with a 309 significant time x severity interaction indicates that the pathway has a different temporal profile in mild/moderate versus severe/critical COVID-19. Our analysis revealed 183 pathways with 310 311 significant (FDR <0.05) time x severity interactions (Supp. Table 9). Notably, the majority of 312 the significant time x severity interactions were in B cells, accounting for 143 of the 183 313 significant pathways. Pathways in B cells and monocytes dominate those showing the 20 most 314 significant time x severity interactions. The two pathways showing the most significant time x 315 severity interaction were the interferon alpha and interferon gamma response in non-class 316 switched memory B cells. Significant time x severity interactions for these pathways are also 317 seen in B cells, class switched B memory cells, cytotoxic CD4+ T cells, NK cells, NK2 cells and NKT cells (Supp. Table 9). These results reflected quantitative differences in the temporal 318 319 gradient of the interferon pathway response, with more severe COVID-19 disease showing 320 higher interferon pathway response early in disease and a steeper decline over time (Fig. 4B). 321

322 In both CD14+ monocytes and B cells we found significant time x severity interactions for 323 "allograft rejection" pathways', and in CD14 monocytes for "graft versus host disease", 324 "asthma", "type 1 diabetes" and "systemic lupus erythematosus". Examination of the genes 325 that make up these pathways revealed that these signals were largely driven by distinct 326 temporal patterns of HLA expression in patients. In patients with a severe/critical clinical 327 course, we observed steep downregulation of HLA class II gene expression over time, 328 compared to either a relatively flat or mild upregulation in patients with a more benign course. 329 HLA class I gene expression was higher in early disease in patients with severe/critical disease than in mild disease but fell further in late disease (Fig. 4C and Supp. Fig. 3A). 330 331 Among other pathways that showed significant time x severity interactions, we noted the

"KRAS signalling up" and "MYC targets" in B cells only, likely reflecting time dependent
 changes in their proliferation during infection that vary according to severity (Supp. Table 9).

These results illuminate how modelling the temporal component provides additional insights by identifying time-dependent severity associations with gene expression that are not apparent in single time-point cross-sectional analyses. Thus, transcriptomic changes are dependent both on time and severity, and the interplay of two, underscoring the importance of serial sampling in gaining a complete picture of the host immune response in COVID-19.

340

341 Longitudinal TCR dynamics

342

343 Given the central role of T cells in antiviral adaptive immunity, we next evaluated clonal T cell 344 dynamics of SARS-CoV-2 infection. The longitudinal nature of our study and single-cell 345 resolution enabled us to be specific in determining paired-chain clones that expanded over the course of COVID-19. A total of 3,137 unique TCR clones that appeared in two or more 346 347 serial samples from the same patient were used to quantify clonal expansion. To increase the 348 probability of identifying TCR clones specific to SARS-CoV-2, we focused on clones that were 349 not present in pre-infection samples, thereby limiting the presence of cross-reactive or bystander T cells. We found that 42% of clones sampled longitudinally had increased clonal 350 351 frequency following day 10 after a positive swab, and that 23% showed a marked expansion 352 where they increased after day 2 of the positive swab, and further after day 10 (Fig. 4D, Supp. Fig. 3B-C, Methods). To investigate whether these clonal expansions were directed against 353 354 SARS-CoV-2, we cross-referenced SARS-CoV-2 specific TCR sequences from the VDJDB 355 database¹⁸ and measured the overlap with clones identified in more than one serial sample 356 within an individual. Clones expanding after day 10 were significantly enriched in SARS-CoV-357 2 specific TCR alpha chains (p=0.0014, two-sided Mann-Whitney test, Fig. 4E) compared to their non-expanding counterparts, while those fulfilling the stricter dual criteria above had an 358 359 almost two-fold increase in antigen-specific TCRs (p=0.006137, Fig. 4F). We next tested the 360 relationship between magnitude of expansion of the longitudinally identified clones and SARS-361 CoV-2 specificity. The fastest expanding clones had the highest proportion of SARS-CoV-2 specific TCR alpha chains (Fig. 4G), indicating that we are capturing the adaptive immune 362 363 response to COVID-19. This SARS-CoV-2 specificity estimate is likely a lower bound to the 364 true number, as experimental data from the database is based on assays with many fewer 365 SARS-CoV-2 peptides than the number of naturally occurring viral antigens. Thus, of the 366 expanding sequences that we recovered that do not match the database, many more are likely 367 to be virus specific.

368

369 Further leveraging our single cell data, we looked for patterns in the TCRs of expanding clones that might be shared across donors. We applied the tool Cell2TCR¹⁹ to our expanded clones 370 371 (excluding MAIT cells, Methods) and found 99 public TCR motifs, where a public TCR motif 372 denotes a group of clonotypes with sufficient sequence similarity to likely recognise the same 373 epitope that was found in two or more patients. Moreover, six TCR motifs were shared 374 between three donors and three motifs between four donors, a scenario which is highly 375 unlikely for randomly sampled TCR clones and provides evidence of strong selective pressure 376 on the adaptive immune response to a common pathogen (Fig. 4H). As we had recruited 377 patients during two distinct phases of the pandemic, we hypothesised that certain TCR motifs 378 might be specific to a particular viral strain and exhibit sharing only across donors from the same cohort (e.g. sampled in 2020 or 2021, respectively). Of the 99 public TCR motifs, 64% 379

380 had donors from a single cohort, including two motifs of Fig. 41 with four donors each. 381 Furthermore, 18% of public motifs contained at least one SARS-CoV-2 specific TCR sequence, underscoring the sensitivity of this approach to analyse the antigen-specific 382 383 response. Our findings are in strong agreement with evidence from a recent SARS-CoV-2 384 Human Challenge Study¹⁹, involving deliberate infection of healthy individuals with SARS-385 CoV-2, which had shown that the antigen-specific response included convergent paired-chain 386 immune receptor motifs. We thus replicate the challenge study results in the context of natural 387 infection and in a larger cohort comprising a clinically relevant vulnerable group consisting of 388 older individuals with underlying comorbidities, which included cases of severe/critical COVID-389 19.

391 As our data was longitudinal, we next investigated the presence of time-restricted, activated T cell types characterised in the context of COVID-19 by Lindeboom *et al*¹⁹. Activated T cell 392 393 states were found to be indicative of de novo T cell activation and harbouring SARS-CoV-2 394 specific TCR sequences. Application of the automated cell state annotation tool Celltypist⁹ 395 revealed 1.927 activated T cells, spanning the CD4+, CD8+, regulatory and MAIT cell 396 compartments and found among 58 ESKD COVID-19 patients (Supp. Fig. 3D). When 397 normalising the counts by cell type and sample numbers and aggregating across time points, 398 we observed a striking lack of activated T cells in pre-pandemic as well as convalescent 399 COVID-19 samples (Fig. 4H). While MAIT cells and regulatory T cells showed a relative 400 enrichment during the first week after positive PCR test, most activated CD4+ and CD8+ 401 appeared only after 10 days. All activated T cell types remained detectable three weeks after 402 positive PCR test but had mostly disappeared again by the time convalescent samples were 403 taken, highlighting the transient nature of these cell states. Activated T cells were further over-404 represented among the most expanded clones (Fig. 4J). This is in line with results from the 405 clinical trial in Lindeboom et al, where activated MAIT cells could be detected as early as 3 davs after exposure to the virus, and circulating activated T cell abundance peaked 10-14 406 407 days after exposure to the virus, with return to baseline after 28 days¹⁹.

408

390

409 Corticosteroids induce dexamethasone-related monocytes in COVID-19

410 411 By the time of the 2021 COVID-19 wave in the UK, glucocorticoid administration with 412 dexamethasone had become standard clinical practice following randomised clinical trials 413 demonstrating that it reduced mortality in patients with COVID-19 requiring supplemental 414 oxygen³. Corticosteroids are known for their broad immunosuppressive effects through 415 several different mechanisms, including inhibiting the release of proinflammatory cytokines²⁰. 416 In vitro experiments have suggested that monocytes and macrophages treated with 417 glucocorticoids can exhibit both anti-inflammatory and inflammation-resolving properties²¹. 418 The effect of corticosteroids on human immune responses at single cell level in vivo has not 419 been studied. Of the 16 patients in the 2021 Cohort, 7 received steroid treatment (Supp. Table 420 1). Patients receiving steroids all had a peak illness severity of severe or critical. This provided 421 us with an opportunity to investigate the effects of steroids at the single cell transcriptomic 422 level over the course of their treatment. 423

Whilst exploring the innate immune response, we isolated the monocyte compartment from the rest of the data and sub-clustered these cells. We identified the emergence of a subset of monocytes that were only seen in COVID-19 positive, severe/critical cases but not in patients with mild/moderate disease (**Fig. 5A-B**). These cells were clearly demarcated on UMAP plots

428 as a distinct population. Differential gene expression analysis between all subsets of monocytes showed this population had transcriptional similarities with monocytes treated ex 429 vivo with dexamethasone²² (Fig. 5C). Compared to classical CD14 monocytes and IFN 430 431 stimulated CD14 monocytes, the dexamethasone-related monocytes (Dex. mono) had lower 432 expression of markers of inflammation such as JUN and CXCL8 as well as lower expression 433 of antigen presenting markers HLA-DRA and HLA-DRB5. Conversely, they showed higher 434 expression of genes relating to anti-inflammatory actions (CD163 and ADAMTS2), anti-435 oxidation (SLC1A3 and SESN1), migration (FPR1 and MTSS1) and phagocytosis (MFGE8 436 and MRC1) (Fig. 5C). Notably, these cells were only present in patients recruited in the 2021 437 Cohort, suggesting they were a direct effect of glucocorticoid treatment and not a 438 consequence of severe COVID-19 itself (Fig. 5A).

439

440 We formally tested the effect of glucocorticoids on differential cell abundance across the 441 monocyte clusters using MiloR, accounting for time from infection²³. We noted that both CD14 442 monocytes and the dex. monos were significantly enriched after glucocorticoid treatment, and 443 the IFN-stimulated CD16 monocytes, C1 CD16 monocytes and IFN-stimulated CD14 444 monocytes were significantly enriched before treatment (Fig. 5D). Using the longitudinal data 445 from only the individuals who were given glucocorticoid treatment, we evaluated the percentage of different monocyte subsets prior to and in the days after treatment. We found 446 447 that, after glucocorticoid administration, there was a trend towards an increased relative 448 abundance of the dex. monos and CD14 monocytes, whilst there was a decrease in both IFN-449 stimulated monocyte populations (Fig. 5E). No trends were observed in other cell types 450 (Supp. Fig. 4 and 5). These results suggest that, along with promoting the emergence of the 451 dex. monos, glucocorticoids could facilitate a reduction of the abundance of interferon-452 stimulated monocytes in severe COVID-19 infection.

453

The dex, monos displayed high RNA and protein expression of CD163 (Fig. 5C and 5F) a 454 455 scavenger receptor that is frequently used to mark 'alternatively activated' or 'M2'-like 456 macrophages²⁴. These macrophages possess regulatory functions which can suppress immune responses and reduce inflammation²⁵. Macrophages treated with glucocorticoids 457 458 have been shown to drive the polarisation of macrophages towards an 'alternatively activated'/M2-like phenotype²⁶. These findings prompted us to further assess transcriptional 459 programs of the dex. monos. We performed pathway enrichment analysis on all monocytes 460 461 based on 15 different macrophage stimulation signatures²⁷. The dex. monos were more 462 associated with transcriptomic patterns associated with stimulation with IL-13, IL-4, ultra-pure 463 LPS+immune complex, glucocorticoid stimulation, supporting their similarity to M2-like 464 macrophages (Fig. 5G). The temporal emergence of the dex. monos and their presence only 465 in the 2021 Cohort strongly suggest that the changes we observed were driven by 466 dexamethasone treatment rather than disease severity.

468 **Discussion**

469

467

Here, we performed CITE-seq and immunoreceptor profiling in ESKD patients with COVID-19 to longitudinally profile the circulating immune cell changes associated with COVID-19 in two temporally distinct cohorts. A unique aspect of our study was the 2021 cohort, where we obtained longitudinal PBMC samples from patients with COVID-19 who were originally sampled as COVID-19 negative controls during 2020 but subsequently became infected during 2021. As a result, we were able to perform intra-individual analysis of the host immune

476 cell PBMC transcriptome comparing pre-infection with acute infection, thus minimising the
477 impact of confounding factors. Another strength of our study was the inclusion of patients of
478 diverse ancestries.

479

480 Using a multi-omic approach, we identified COVID-19-associated changes in the cellular 481 composition of PBMC in ESKD patients including increased relative abundance of naive B 482 cells and a decreased relative abundance of total monocytes, CD8+ memory and CD4+ CTL 483 T cells. This decrease in the relative numbers of circulating monocytes following infection was 484 also observed in a recent experimental medicine challenge study, involving deliberate infection of healthy individuals with SARS-CoV-2¹⁹. COVID-19 was associated with widespread 485 transcriptomic changes in a wide variety of cell types. Many of these reflect the activation of 486 487 inflammatory pathways, including the type 1 interferon pathway and cellular activation and 488 proliferation. Overall, the COVID-19-associated changes in ESKD patients were similar to 489 those reported in other studies, but we did identify some changes that, to our knowledge, have 490 not been previously reported. For example, gene expression pathway analysis highlighted 491 significant negative enrichment of the "Orexin Receptor Pathway" in COVID-19 positive ESKD 492 patients versus uninfected ESKD patients across several innate immune cell types. Many of 493 the leading-edge genes contributing to the "Orexin receptor pathway" term are also involved 494 in other pathways, which makes interpretation of this finding more challenging. Orexin receptor 495 signalling is well-characterised in neurological diseases such as narcolepsy, but there is also 496 evidence that Orexins can have immunological effects that may be relevant in the context of 497 COVID-19^{28,29}.

498

499 We also identified numerous pathways associated with COVID-19 severity in ESKD, 500 particularly in monocytes and B cells. Notably, we found many more pathways associated with 501 severity in B cells than in T cells. In addition, severe COVID-19 was associated with a higher 502 relative abundance of antibody-secreting B cells and with higher expression of genes involved 503 in cell division. In CD14+CD16- monocytes, we observed elevated PLAC8 expression in 504 severe COVID-19. High PLAC8 expression makes lung cells more permissive for SARS-CoV-2 infection in vitro¹⁶. In line with this, a genome-wide CRISPR knockout screen identified 505 506 PLAC8 as an essential factor for infection with a different coronavirus, swine acute diarrhoea syndrome coronavirus (SADS-CoV)³⁰. While SARS-CoV-2 predominantly infects epithelial 507 508 cells, it has also been detected in macrophages and T cells³¹. Together with this work on the 509 cell biology of PLAC8 in viral infection, our observation that expression changes with disease 510 severity in monocytes raises the possibility that modulating PLAC8 expression may provide a 511 therapeutic opportunity to prevent infection of both epithelial and immune cells.

512

513 Multi-omic measurements allowed us to identify instances of negative correlation between immune cell gene expression and levels of the corresponding plasma protein. For example, in 514 515 severe COVID-19 the most down-regulated gene in monocytes was TNF (encoding TNF-516 alpha), yet conversely, TNF-alpha was significantly upregulated in the plasma from the same 517 blood draw. Potential explanations for this uncoupling include negative feedback, or that other 518 cell types could be contributing to circulating TNF-alpha pool (e.g. endothelial cells, tissue 519 macrophages). This observation underlines the complementary value of combining multi-omic 520 data, since plasma proteins reflect protein production by a wide variety of tissues other than blood cells³². Since our data are observational, we cannot determine if elevated circulating 521 522 TNF-alpha is a cause or a consequence of severe COVID-19. Nevertheless, since TNF-alpha 523 blocking drugs are in routine clinical use in inflammatory diseases such as rheumatoid arthritis,

524 our results suggest there may be value in evaluating the repurposing of these medications for 525 COVID-19³³.

526

Longitudinal analysis of changes in cell type abundance showed a peak in cells showing an interferon-activated gene signature in the first week of illness followed by a waning, again consistent with that seen in other work¹⁹. Gene expression pathways which displayed distinct temporal profiles according to clinical severity were predominantly found in B cells and monocytes.

532

533 Longitudinal analysis also revealed the time-restricted appearance and expansion of T cells 534 with likely SARS-CoV-2 specificity. Leveraging the large number of longitudinal samples, we 535 identified the emergence of public T cell clones with a restricted TCR repertoire that are shared 536 across patients. Cross-referencing the TCRs with SARS-CoV-2 specific databases, we found 537 most matches among T cells that strongly expand in the days following a positive PCR test, 538 and a significant enrichment of matches compared to pre-pandemic samples. Our results 539 support the hypothesis that both TCR chains together determine antigen specificity, which we 540 were able to capture jointly using single-cell sequencing, as expanding clones could further 541 be grouped into shared TCR motifs with high sequence similarity in both chains. In addition, a 542 recently activated T cell phenotype is overrepresented in that same population. We expand 543 on existing knowledge from the first human COVID-19 challenge study by analysing a larger 544 patient cohort, which included cases of severe disease, as well as replicating several key 545 findings in the context of natural infection. In addition, we identified longitudinal expansion of 546 some clones that are not recorded as SARS-Cov2-specific in the VDJDB database. These 547 could potentially be previously undescribed SARS-CoV2-specific T cells, given that we 548 analysed a large number of longitudinal samples that included patients with severe/critical 549 disease and also diverse ancestry. An alternative explanation is that the expansion of some 550 TCR clones was driven by bystander activation secondary to the inflammatory milieu. Thus, 551 our study generates hypotheses for further functional work.

552

An important finding of this study was the identification of a distinct population of monocytes 553 554 that emerged after glucocorticoid therapy. These were not observed in any patients in the 555 2020 Cohort, before the introduction of glucocorticoid therapy as standard of care, and their 556 emergence in the 2021 Cohort occurred rapidly after glucocorticoid administration. These 557 findings could have implications beyond COVID-19. Corticosteroids are frequently used to suppress inflammation and they have pleiotropic effects on immunity that are not fully 558 559 understood despite their long-standing clinical use. Therefore, being able to probe the effects 560 of steroid treatment in humans using single cell resolution multi-omic technologies provides 561 potential insights into their mode of action. This may facilitate rational drug design of 562 compounds that target these pathways without steroid side effects. Here, we demonstrated 563 that glucocorticoids could promote the emergence of a transcriptionally distinct subpopulation 564 of monocytes. An outstanding question remains the functional properties of these steroid-565 induced cells such as their ability to traffic to tissues and modulate inflammatory responses. 566

567 ESKD patients have increased susceptibility to sepsis and impaired vaccination response (for 568 example, hepatitis B vaccination)^{8,34}. Reports on neutralising activity against the delta variant 569 following SARS-Cov-2 vaccination showed an impaired response of haemodialysis patients 570 compared with healthy controls in response to the AZD1222 vaccine³⁵ and an impaired 571 neutralising response to the omicron variant with heterologous boost regimes consisting of

two doses of the AZD1222 followed by the mRNA vaccine BNT162b2³⁶. Vaccination strategies
have been very successful in reducing morbidity and mortality, but widespread transmission
of SARS-CoV-2 continues. As new variants emerge, certain patient groups, such as those
with ESKD will have a higher risk of both contracting infection and of experiencing a severe
disease course, underscoring the importance of studying such patient groups.

577

578 Our study has some limitations. Our data are observational and thus cannot delineate whether 579 changes in cell populations or gene expression are pathogenic drivers or downstream 580 consequences of the systemic inflammatory response. Observational data are also vulnerable 581 to the effects of confounding factors. Our use of paired pre-infection and infection samples in the analysis of the Wave 2 partially mitigates this, but unknowable confounders such as viral 582 583 exposure at the time of infection may nevertheless impact the magnitude of the host immune 584 response. In addition, we studied peripheral blood immune cells due to accessibility, but these 585 may not always reflect those at the site of tissue inflammation. We did not have a comparator 586 group of ESKD patients with another infection, so we cannot determine whether the changes 587 we observed are specific to COVID-19. Finally, this was a single centre study.

588

In summary, we characterised the longitudinal host immune response in COVID-19 in a clinically vulnerable group through multi-omic technologies. These data illuminate the temporal dynamics of the response to infection, and how these diverge in mild versus severe disease. Our results reveal the impact of glucocorticoid therapy, with the emergence of a specific monocyte subpopulation following treatment. The data here will provide a valuable resource for the research community.

595

596 Acknowledgements

597 This work was funded by a UKRI-DHSC COVID-19 Rapid Response Rolling Call (MR/V027638/1) (to J.E.P.), funding from the UK Coronavirus Immunology Consortium (UK-598 599 CIC) and Wellcome Human Cell Atlas Strategic Science Support (WT211276/Z/18/Z), and the 600 NIHR Imperial Biomedical Research Centre (BRC). The views expressed are those of the 601 authors and not necessarily those of the NIHR or the Department of Health and Social Care. 602 M.H. is funded by Wellcome (221052/Z/20/Z, 215116/Z/18/Z), the Lister Institute for 603 Preventive Medicine, and NIHR and Newcastle Biomedical Research Centre. L.M.D is 604 supported by the European Union's Horizon 2020 research and innovation programme under 605 the Marie Skłodowska-Curie grant agreement No 955321. J.E.P. is supported by a fellowship 606 from the Medical Research Foundation (MRF-057-0003-RG-PETE-C0799). M.C.P. is a 607 Wellcome Trust Senior Fellow in Clinical Science (212252/Z/18/Z). C.L.C was supported by 608 an Auchi Clinical Research Fellowship.

609

610 Author contributions

611 Conceptualisation, M.B., S.A.T, M.H, M.R.C, J.E.P; Investigation, E.St., N.B.B, M.C, A.P.,

612 E.P., T.M and A.P. ; Methodology, J.R.F, B.J.S., J.G., Resources, C.L.C., N.M-T., M.P. S.M.,

613 M.W. and E.Sa. ; Formal analysis, E.St., E.M-D., L.M.D., R.G.H.L., Z.K.T., W.M.T., S.B. and

- 614 D.C.T.; Writing, E.St., E.M-D., L.M.D., R.G.H.L., Z.K.T., W.M.T., D.C.T. and J.E.P.; Editing:
- 615 M.C.P., M.B., S.A.T., M.H. and M.R.C.; Supervision, M.B., S.A.T., M.H., M.R.C, D.C.T. and 616 J.E.P.
- 617
- 618
- 619

620 **Declaration of interests**

S.A.T is on the advisory board for Cell Genomics. L.M.D., R.G.H.L. and S.A.T. are inventors
on a filed patent that is related to the detection and application of activated T cells. In the past
three years, S.A.T. has received remuneration for Scientific Advisory Board Membership from
Sanofi, GlaxoSmithKline, Foresite Labs and Qiagen. S.A.T. is a co-founder and holds equity
in Transition Bio and Ensocell. From 8 January 2024, S.A.T is a part-time employee of
GlaxoSmithKline. The other authors have no conflicts of interest.

628 Supplemental information

- 629 Figures S1-S6 and Tables S1-S9.
- 630 631 Figure Legends
- 632

627

633 Fig. 1: Study Overview.

634 A) Schematic of the study design showing the recruitment of both cohorts and how their samples were processed in the laboratory then analysed. Neg. control = COVID-19 negative 635 636 ESKD patient. Figure created using Biorender.com. B) Timing of blood sampling in relation to 637 illness onset. Colours indicate the COVID-19 severity over time. 'X' with an adjacent arrow indicates death during the hospital admission occurring at >30 days. C) UMAP showing the 638 639 detailed annotations of B cells, myeloid and progenitors and T cells, respectively. ASDC = AxI 640 Siglec dendritic cell, MAIT = mucosal-associated invariant T cell, ASC = antibody secreting 641 cell, sw. mem. = switched memory, CTL = cytotoxic T lymphocyte, T g/d = gamma delta T cell, 642 EMRA = terminally differentiated effector memory T cell, ILC = innate lymphoid cell, mono = 643 monocyte, int. = intermediate.

644

Fig. 2: Cell type abundance and DEG/pathway analysis for positive cases versus negative controls.

A-H) Bar charts displaying relative numbers of cells that significantly changed in abundance 647 648 in week 1 of COVID-19 infection compared to a control group of COVID-19 negative ESKD patients. *P \leq 0.05, **P \leq 0.01, ***P \leq 0.001. I) Heatmap of gene expression pathways 649 significantly (FDR <0.05) associated with COVID-19 positivity. Cell labels above plot denote 650 651 broad cell annotations and labels below denote more granular cell annotations. R = reactome, 652 WP = wiki pathways, K = KEGG, NABA = Alexandra Naba and PID = pathway interaction 653 database. J) Dot plot displaying the expression of the leading-edge subset of genes that 654 contributed to the term "Orexin Receptor Pathway" for COVID positive and negative patients. 655 Mono = monocytes.

656

Fig. 3: Cell type abundance and DEG/pathway analysis for severity of positive cases.

A) Bar chart displaying the relative abundance of dividing antibody secreting B cells for mild 658 659 and moderate patients compared to severe and critical patients. P = 0.017 B) Heatmap of pathways significantly (FDR < 0.05) associated with COVID-19 severity. Cell labels above plot 660 661 denote broad cell annotations and labels below denote more granular cell annotations. R = 662 reactome, WP = wiki pathways, K = KEGG and PID = pathway interaction database. C) Dot 663 plot displaying the expression of differentially expressed genes relating to severity in all 664 monocyte populations. D) Left: Boxplots of TNF RNA counts in monocytes from the scRNA-665 seq dataset and normalised plasma TNF-a protein abundance measured with Olink 666 immunoassays (n=57 samples from 21 individuals with both RNA and plasma protein levels measured). Right: correlation between TNF gene expression and TNF-a plasma protein levels. 667

668 (Pearson r -0.15) **E)** Left: dot plot displaying gene expression of *AREG* in CD14+ monocytes 669 stratified according to COVID-19 severity at the time of sampling. Right: dot plot displaying 670 gene expression of *PLAC8* in CD14+, CD16+ and intermediate monocytes split, again 671 stratified according to COVID-19 severity.

672

673 Fig. 4: Longitudinal gene expression and TCR trajectories

A) Dot plots displaying the significant cell type abundance changes across COVID-19 infection 674 675 compared to pre-infection samples for cells that have an interferon and non-interferon 676 stimulated counterpart. Time since onset of disease is either time since display of first 677 symptom or positive test (whichever is earliest). B) Estimated marginal mean of the effect of 678 time from infection by severity group for the expression of IFN alpha and IFN gamma pathway genes for cell types with significant time x severity interaction. Time since onset of disease is 679 680 either time since display of first symptom or positive test (whichever is earliest). C) Heatmap 681 displaying 10 genes from multiple pathways (Allograft rejection, Asthma, Graft versus host disease. Type 1 diabetes, and Systemic Lupus Erythematosus) that had a significantly 682 683 different temporal profile in mild vs severe disease (linear mixed model, FDR < 0.05) in CD14 684 monocytes. Colour indicates LMM estimated marginal means over time, stratified by patient 685 group (n = 130 samples from 37 individuals). Genes are clustered based on the temporal profile of the discordance between mild/moderate and severe/critical disease. Time since 686 687 onset of disease is either time since display of first symptom or positive test (whichever is 688 earliest). D) Absolute numbers of clones considered for longitudinal analysis and expanded 689 clone counts. E) Proportion of SARS-CoV-2 specific clones among all clones, stratified by 690 whether the clone expanded after day 10 following positive PCR test. Specificity was 691 determined as a perfect match with a TCR alpha chain from the SARS-CoV-2 database 692 VDJDB. Significance with two-sided Mann-Whitney test: p=0.0014. F) As for (C) but stratifying 693 by whether a clone was expanded after day 2 and further after day 10. G) SARS-CoV-2 specific clone proportion among fastest increasing clones. Clones were sorted by decreasing 694 695 expansion magnitude pre/post day 10 following positive PCR test (Methods). Baseline of 696 matches with database from pre-pandemic samples shown in dashed line. Specificity was 697 determined as a perfect match with a TCR alpha chain from the SARS-CoV-2 database 698 VDJDB. H) Sequence logos of 3 most shared paired-chain TCR motifs, with number of 699 individuals and number of unique clones sharing the motif mentioned. Letter height indicates 700 frequency of AA at that position across T cells pertaining to the motif. AAs are coloured by 701 side chain chemistry: Acidic (red), basic (blue), hydrophobic (black), neutral (purple), polar 702 (green). AA: amino acid. I) Distribution of predicted activated T cells across days since positive 703 swab result. T cell counts were normalized by number of cells and samples, cell states were 704 predicted using Celltypist (Methods). J) Activated T cell state proportion among fastest 705 increasing clones. Clones were sorted by decreasing expansion magnitude pre/post day 10 706 following positive PCR test (Methods). Baseline proportion of activated T cells from pre-707 pandemic samples shown in dashed line.

708

709 Fig. 5: Dexamethasone treatment promotes steroid associated monocytes

A) UMAPs displaying all subsets of monocytes; coloured by subset (top), patient cohort
(bottom left), COVID-19 status (bottom middle) and severity (bottom right). B) Bar charts
displaying proportions of all monocytes grouped by mild/moderate and severe/critical severity.
C) Dot plots displaying gene expression (left) and protein expression (right) in CD14
monocytes, IFN-stimulated CD14 monocytes and the dexamethasone associated monocytes
(Dex. mono). D) Beeswarm plot displaying the differential abundance of monocyte subsets for

716 samples from patients that were administered steroids, before and after treatment. E) Line 717 charts displaying the percentage of monocyte subsets across the days before and after 718 administration of steroids. Line colours represent different patients. F) Dot plot displaying the 719 expression of monocyte marker genes in all monocyte subsets. G) Heat map displaying gene 720 module scores for CD14 monocytes, IFN-stimulated CD14 monocytes and the 721 dexamethasone associated monocytes (Dex. mono).

722

723 Supplementary Figure 1: Cell demultiplexing and annotation

A. Heat map showing the overlap of manual versus predicted cell annotations. B. Dot plots

- displaying gene (top) and protein (bottom) expression of markers for myeloid and
- haematopoietic cells. C. Dot plots displaying gene (top) and protein (bottom) expression of markers for B cells. D. Dot plots displaying gene (top) and protein (bottom) expression of
- 728 markers for T and innate lymphoid cells.
- 729

Supplementary Figure 2: Expression of genes contributing to pathways in CD14 monocytes and B cells

732 A. Dot plot displaying the expression of genes that contribute to the Kegg 'Systemic Lupus 733 Erythematosus" pathway in CD14 monocytes. B. Dot plot displaying the expression of genes 734 that contribute to the Kegg 'Type 1 Diabetes Mellitus" pathway in CD14 monocytes. C. Dot 735 plot displaying the expression of genes that contribute to the Kegg 'Asthma" pathway in CD14 736 monocytes. D. Dot plot displaying the expression of genes that contribute to the Kegg 'Graft 737 Versus Host Disease" pathway in CD14 monocytes. E. Dot plot displaying the expression of 738 genes that contribute to the Kegg 'Allograft rejection" pathway in CD14 monocytes. F. Dot plot 739 displaying the expression of genes that contribute to the Kegg 'Allograft rejection" pathway in 740 B cells.

741

742 Supplementary Figure 3: Longitudinal analysis

A. Clonal frequency dynamics for all clones expanded after day 2 post positive PCR result, as
well as a trendline. B. Clonal frequency dynamics for all clones expanded after day 2 post
positive PCR result and further expanded after day 10, as well as a trendline. C. Number of
activated T cells according to Celltypist predictions, split by T cell type.

747

748 Supplementary Figure 4: Trend of cell proportions during steroid treatment

- Line charts displaying the percentage of cell subsets across the days before and after administration of steroids. Line colours represent different patients
- administration of steroids. Line colours represent different patients.

752 Supplementary Figure 5: Trend of cell proportions during steroid treatment

- Line charts displaying the percentage of cell subsets across the days before and afteradministration of steroids. Line colours represent different patients.
- 755

Supplementary Figure 6: Estimated ancestry calculated using genotype compared to self-reported by patient.

- A. PCA plot of genetically estimated ancestry of each patient calculated using genotypes. B.
 PCA plot of the ancestry reported by the patients themselves.
- 761 **Supplementary Table 1:** Metadata from individuals sampled.
- 762

760

763 **Supplementary Table 2:** List of antibodies included in the Total-seq panel.

764	
765	Supplementary Table 3: Statistical tests from cell abundance analysis of cases versus
766	controls.
767	
768	Supplementary Table 4: Differentially expressed genes for each cell type for cases versus
769	controls.
770	
771	Supplementary Table 5: Gene set enrichment pathway analysis for each cell type based on
772	DEGs from Supp. Table 4.
773	
774	Supplementary Table 6: Statistical tests from cell abundance analysis of severity.
775	
776	Supplementary Table 7: Differentially expressed genes for each cell type for severity.
777	
778	Supplementary Table 8: Gene set enrichment pathway analysis for each cell type based on
779	DEGs from Supp. Table 7.
780	
781	Supplementary Table 9: Gene set enrichment pathway analysis of time x severity
782	interactions.
783	
784	Materials and Methods
785	
786	Ethical approval
787	
788	All participants (patients and controls) were recruited from the Imperial College Healthcare
789	NHS Trust Renal and Transplant Centre and its satellite dialysis units, London, United
790	Kingdom, and provided written informed consent prior to participation. Study ethics were
791	reviewed by the UK National Health Service (NHS) Health Research Authority (HRA) and
792	Health and Care Research Wales (HCRW) Research Ethics Committee (reference
793	20/WA/0123: The impact of COVID-19 on patients with renal disease and immunosuppressed
794	patients). Ethical approval was given.
795	
796	Patient cohorts
797	
798	We recruited two cohorts of ESKD patients with COVID-19. All patients were on haemodialysis
799	prior to acquiring COVID-19. The first cohort ('2020/Wave 1') were recruited during the initial
800	phase of the COVID-19 pandemic (April-May 2020). We collected 61 serial blood samples

phase of the COVID-19 pandemic (April-May 2020). We collected 61 serial blood samples
 during acute infection for 21 patients with COVID-19. Three samples were collected for 19 of
 these patients; two samples were collected for the other two individuals. We also
 contemporaneously recruited 37 non-infected ESKD patients on haemodialysis to provide a
 control group.

805

The second cohort ('2021/Wave 2') were recruited during the resurgence of cases in January-March 2021. This cohort, which consisted of 16 ESKD patients with COVID-19, had all been recruited as part of the COVID-19 negative control group during the 2020 wave, and so a preinfection sample collected in April/May 2020 (8-9 months preceding infection) was also available for 13 patients. For these patients, samples were systematically acquired at regular intervals (median 5 samples per patient, collected every 2-3 days over the course of the acute

infection). Additionally, for 10 of these 16 patients, we acquired convalescent samples
approximately 2 months following the acute COVID-19 episode. 3 individuals in this cohort
had received one dose of the COVID-19 vaccine, however their first blood sample was taken
within an average of 5 days so there was an unlikely chance this had an effect on their immune
response to the infection.

817

818 Clinical severity scores

819

820 Severity scoring was performed based on WHO classifications (WHO clinical management of 821 COVID-19: Interim guidance 27 May 2020) adapted for clinical data available from electronic 822 medical records. 'Mild' was defined as COVID-19 symptoms but no evidence of pneumonia 823 and no hypoxia. 'Moderate' was defined as symptoms of pneumonia or hypoxia with oxygen 824 saturation (SaO2) greater than 92% on air, or an oxygen requirement no greater than 4 L/min. 825 'Severe' was defined as SaO2 less than 92% on air, or respiratory rate more than 30 per minute, or oxygen requirement more than 4 L/min. 'Critical' was defined as organ dysfunction 826 827 or shock or need for high dependency or intensive care support (i.e. the need for non-invasive 828 ventilation or intubation). Severity scores were charted throughout a patient's illness. We 829 defined the overall severity/clinical course for each patient as the peak severity score that 830 occurred during the patient's illness.

831 PBMC isolation protocol

Peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation using Lymphoprep (STEMCELL Technologies, Canada). Approximately 20 ml of blood were diluted 1× with phosphate buffered saline (PBS) with addition of 2% fetal bovine serum (FBS) and layered on top of 15 ml of Lymphoprep solution. The samples were then centrifuged at 800 g for 20 min at room temperature without break. PBMCs were collected from the interface and washed twice with PBS/2%FBS. PBMCs were cryopreserved in 1 ml freezing medium (FBS 10% DMSO) and stored in liquid nitrogen.

839 PBMC processing and CITEseq

840

841 Samples collected during 2020 wave

842 Frozen PBMCs were thawed by adding a small volume of ice-cold PBS to PBMC samples and 843 transferred to a falcon tube containing 35 mL of ice-cold PBS. Samples were then centrifuged 844 and counted. Dead cells were removed using the EasySep Dead Cell Removal kit (Stem Cell 845 Technologies) according to the manufacturer's protocol. Cells were then counted again and 846 40,000 cells from each sample were pooled together in batches of seven with the aim for each 847 pool to contain ~300.000 cells, ensuring each pool had a different combination of genotypes for simple demultiplexing. Pooled cells were then stained with Fc Receptor Blocking Solution 848 849 (Biolegend) and then with TotalSeq[™]-C Human Universal Cocktail V1.0 (Biolegend) 850 according to the manufacturer. Cells were then washed once with PBS and then counted. 851 Each pool was loaded across two channels of a Chromium Chip (10x Genomics), using Single 852 Cell 5' V2 kits, to achieve a recovery of 10,000 cells per sample.

853

854 Samples collected during 2021 wave

Frozen PBMCs were thawed at 37°C until a small ice crystal remained. Samples were then transferred to another tube and ten times the volume of pre-warmed RF-10 media (RPMI 857 (Sigma) supplemented with 10% (v/v) fetal calf serum (Life technologies), 100U/ml Penicillin 858 (Sigma), 100 µg/ml Streptomycin (Sigma) and 1% (v/v) L-Glutamine) was added dropwise. Cells were then centrifuged and counted. Dead cells were removed using the EasySep Dead 859 860 Cell Removal kit (Stem Cell Technologies) according to the manufacturer's protocol. Cells were then counted again and 250,000 cells from each sample were pooled together in batches 861 862 of four using a leave-one-out strategy for simple demultiplexing. Pooled cells were then stained with Fc Receptor Blocking Solution (Biolegend) and then with TotalSeg™-C Human 863 864 Universal Cocktail V1.0 (Biolegend) according to the manufacturer. Cells were then washed 865 three times with Flow Buffer (Dulbecco's phosphate buffered saline (PBS)(Sigma) 866 supplemented with 2% (v/v) FCS and 2mM EDTA (Sigma)) and then counted. Each pool was 867 loaded across two channels of a Chromium Chip (10x Genomics), using Single Cell 5' V2 kits, 868 to achieve a recovery of 10,000 cells per sample.

869

870 Library Preparation and Sequencing

871

Gene expression, cell surface protein, TCR and BCR libraries were generated according to
the manufacturer's protocols. All libraries were sequenced using a NovaSeq 6000 to achieve
a minimum of 20,000 reads per cell for gene expression libraries and 5,000 reads for cell
surface protein, TCR and BCR libraries.

876

877 Bioinformatics Pre-processing

878

879 We jointly aligned the antibody-derived tags (ADT) and gene expression libraries from CITE-880 seq experiments using CellRanger 4.0, using the reference 10X Genomics provided with the 881 release of CellRanger 3.0, and the ADT barcode reference provided by the supplier. Single 882 cell TCR and BCR sequencing data was aligned using CellRanger 4.0 using the GRCh38 VDJ reference provided by 10X Genomics. We used Seurat V4.1.0³⁷ to import gene expression 883 884 and ADT counts. Low quality cells were excluded by removing droplets with either fewer than 885 1000 RNA UMIs, or fewer than 200 RNA features detected, or with more than 10% of their RNA UMIs mapping to mitochondrial genes. SoupX³⁸ was used to remove signals from 886 887 ambient RNA and background antibody staining. SoupX parameters 'soupQuantile' and 888 'tfidfMin' were set to 0.25 and 0.2, respectively, and lowered by decrements of 0.05 until the 889 contamination fraction was calculated using the 'autoEstCont' function. Corrected gene 890 expression and ADT counts were then scaled to 10000 UMIs per cell and log1p transformed. 891

892 Sample demultiplexing

We used souporcell v2.0³⁹ to perform genotype-based demultiplexing of pooled PBMC 893 894 libraries to assign donor identifiers to each single cell transcriptome. To ensure high 895 reproducibility of the genotype-decomposition, we merged the sequencing data from each set 896 of replicates of the same donor pool prior to souporcell analysis. We used pysam v0.17.0 to amend cell barcodes with original library identifiers and to merge bam files. Using the merged 897 898 bam files, we ran *souporcell* using the provided set of common variants, with remapping 899 disabled and with the appropriate number of expected genotypes. To assign a donor identifier 900 to each souporcell genotype cluster we leveraged the pooling strategy of donors per library which was designed in such a way that every donor was present in a unique combination of 901 pools. We used the cardelino R package ⁴⁰ to import genotypes and perform pairwise 902 903 comparisons of all identified souporcell genotype clusters, to identify highly similar genotype 904 clusters in different pools that likely originated from the same donor, which was then given a

donor label based on the combination of pools in which the genotype was detected. Genotypes
that were not resolvable due to missing or low-quality data, were excluded from downstream
analyses.

908

We detected a total of 1337786 cells with at least 200 genes quantified. We next applied stringent filtering on cell quality to remove cells with more than 10% mitochondrial reads and cells with less than 1000 UMIs quantified. In addition, we only kept cells with a genotype / patient id assignment using souporcell, and that did not cluster in doublet enriched leiden clusters during the manual annotation process. This resulted in a dataset of 588389 highguality cells from 63 patients and 198 samples that were used for the reported analyses.

915

926

Single-cell Quality Control - Myeloid and non-immune haematopoietic cell compartment:

918 Annotation of myeloid and progenitor compartment was performed using scanpy⁴¹ (v1.8.2). The dataset was initially normalized, and log transformed, and then filtered for highly variable 919 920 genes (scanpy.pp.highly variable genes; min mean=0.0125, max mean=3, min disp=0.5) 921 and scaled (scanpy.pp.scale, max_value=10). Dimensionality reduction was performed using 922 principal component analysis (PCA; scanpy.tl.pca), and integration was done using harmony 923 ⁴² (*harmonypy*, v0.0.6). Clustering was performed using the Leiden ⁴³ algorithm (*leidenalg*, 924 v0.8.9). The marker genes for each cluster were examined using the function 925 'scanpy.tl.rank genes groups' and each cluster was manually annotated.

927 Single-cell Quality Control - T and NK cell compartment:

928 The T and NK cell compartment quality control and annotation was performed using the Seurat 929 (v4.1.1) workflow ³⁷. The expression data was normalized, and log transformed (normalized to 10,000 counts per cell), 2000 highly variable genes were selected (FindVariableFeatures 930 function. selection.method = 'vst'), from which TCR and V(D)J genes were excluded. Prior to 931 932 scaling the gene expression data, unwanted sources of variation in the form of total read count 933 and percentage of mitochondrial genes were regressed out (using ScaleData function, vars.to.regress argument). Integration of sequencing samples ('orig.ident') using harmony 42 934 (v1.0) was carried out on the first 30 principal components of the expression data. K-nearest 935 936 neighbors (KNN) and shared nearest neighbors (SNN) graphs were calculated from the 937 harmony adjusted PCs (FindNeighbours function). Finally, cells were clustered using the 938 Leiden algorithm (FindClusters function, method='igraph', algorithm=4, requiring 'leidenalg' python package) and visualized via non-linear dimension reduction UMAP. Clusters were 939 940 manually annotated using canonical marker genes through an iterative process of re-941 clustering, annotation, identification of potential doublets (presence of distinct cell type marker 942 genes) and re-clustering. CITE-seq marker proteins CD45RA and CD45RO were used in the 943 annotation of T EMRA and other memory T cells respectively. All other markers used for 944 annotations were based on mRNA expression data.

945

946 Single-cell Quality Control - B cell compartment:

The B cell compartment was integrated using *scVI* (v.0.19.0) ⁴⁴ with sequencing samples ('*orig.ident*') as the batch key and raw count data as input. Samples from two individuals were observed to not integrate well and they were subsequently identified to be samples from patients with benign chronic lymphocytic leukaemia and were removed from all downstream analyses (**Table S1**). Percentage mitochondrial content and total counts were provided as continuous variables to the *scVI* model. Feature selection prior to setting up the scVI model

953 was performed as per standard procedures in scanpy.pp.highly variable genes with 954 min_mean=0.0125, max_mean=3, min_disp=0.5, using the log transformed normalized expression data (normalized to 10,000 counts per cell). BCR V(D)J genes were also removed 955 956 from the highly variable features. Expression of canonical B cell and ASC marker genes and 957 non-B cell markers were then assessed to manually determine potential multiplets, over 958 iterative rounds of sub-clustering. The annotations were also assessed against a publicly available bulk RNAseq gene set of major PBMC cell types ⁴⁵. In addition, the single-cell scores 959 960 computed after enrichment of the bulk RNA-seq signatures were fitted into a two-component 961 Gaussian mixture model (max iter=1000, covariance type='full') which distinguished ASCs 962 from non-ASC B cell clusters. Subsequent sub-clustering and annotations were performed on the ASCs and non-ASCs separately. To annotate the non-ASC cell clusters, mRNA and 963 964 surface molecule expression for select targets (CITE-seq; CD11C and CD27), along with the Monaco et al. ⁴⁵ peripheral blood B cell signatures. Isotype usage was checked using the 965 966 single-cell and BCR-seq information and used to manually update the cell type annotations, 967 ensuring that naive B cells, non-switched memory B cells and IgM ASCs are only associated with IgM and/or IgD while switched memory B cells and IgA/IgG ASCs are only associated 968 969 with IgG/IgA isotypes. Other antibody isotype expressing ASCs (IgD/IgE) are labelled as 970 'B ASC others'.

971 Integration of Olink Plasma Proteomics

972

A subset of Wave 1/2020 Cohort (45 individuals, 85 samples) had plasma proteomics
measures from 5 Olink Proteomics Target 96 panels: 'cardiometabolic', 'cardiovascular 2',
'cardiovascular 3', 'inflammation' and 'immune response'. The Olink proteomics data for these
samples has previously been described¹⁴.

977

979

978 Longitudinal analysis

We defined time from infection as the time from first symptoms, or time from first positive nasal
swab if the latter preceded symptoms (since some cases of COVID-19 were identified by
screening procedures in place for patients attending haemodialysis).

983

995

For longitudinal analysis of enrichment of MSigDB (v7.5) Hallmark, KEGG and Reactome 984 985 genesets ⁴⁶, the single-cell data was separated to each cell type and the raw count data was aggregated by sample using 'scuttle::aggregrateAcrossCells' (v1.9.0). Only samples with 986 987 more than 10 cells were used for downstream analysis. The pseudo-bulked data was then log 988 transformed and normalized using 'scuttle::logNormCounts' and converted to a module score 989 using 'Seurat::AddModuleScore'. The module scores were then tested for differential 990 enrichment over time according to severity strata, using a general linear mixed-effect model 991 with 'Ime4:Imer' using the following formula:

992geneset ~ sex + age_scaled + (1|individual_id) + centre +993PC1_nonafricanVsAfrican + PC2_asianVsEuropean +994splines::bs(time_from_infection, degree = 2) * grouped_severity

996 "Grouped severity" represents overall clinical course, defined by peak illness severity, 997 binarised into either severe/critical or mild/moderate. The estimated marginal means for the 998 first 21 days from infection for the relevant genesets were computed using 999 'emmeans::emmeans' with '*time_from_infection*' by '*grouped_severity*'.

1000

1001 All P values were adjusted using the Benjamini-Hochberg procedure ⁴⁷.

1002

1004

1003 Cell type composition analysis - linear mixed effect model

- 1005 The cell type abundances per sample were modelled using a generalised linear mixed model using a poisson outcome as described in Yoshida et al ¹¹. We fitted log₂ transformed age, and 1006 1007 random effect terms on biological sex and inferred ethnicity, to account for collinearity with 1008 features of interest. We also fitted a random effect term on the donor identifier to account for 1009 donor-to-donor variation but captured the paired effects between longitudinal samples from 1010 the same donor. To perform longitudinal analyses, we modelled weeks since onset of disease (onset of symptoms or positive test, whichever came first) as categorical features, and scaled 1011 1012 the conditional distribution of fold change estimates to the pre-infection samples that were 1013 available, and the pre-infection standard deviation was multiplied by the standard deviation of 1014 each other timepoint factor level to account for the increased variance that is introduced by 1015 scaling.
- 1016

1017 Genetic principal component analysis

1018

1019 To overcome missing self-reported ethnicity data for some donors, we used PCA on 1020 genotyping data to quantify and infer genetic ancestry. We took the souporcell cluster genotypes of all donors and converted them into a numerical matrix to perform PCA on using 1021 1022 *FactoMineR V2.4*⁴⁸. We then mapped self-reported ethnicity onto the genetic PCA results. 1023 This revealed that principal component 1 separated individuals with self-reported ethnicities 1024 indicating African ancestry from individuals with other ethnicities, while principal component 2 1025 separated individuals of self-reported Asian ancestry from those with self-reported European ancestry. To adjust for the potential confounding effects of ethnicity (since ethnicity is 1026 1027 associated with higher risk of severe and fatal COVID-19), we included these 2 principal 1028 components (continuous variables) as covariates in all linear mixed models (Table 1, Supp. 1029 Fig. 6).

1030

1031 Differential abundance testing - steroid treatment

1032

1033 To examine the effect of steroid treatment on the cell abundance, MiloR package (v.0.99.0)²³ 1034 was used. The monocyte population was sub-setted to include only the samples from COVID-1035 19 positive patients who received the steroid treatment during 'Wave 2' of COVID-19. A KNN 1036 graph was constructed using the function 'buildGraph' (k=30, d=30) and the cells were 1037 assigned to the neighbourhoods on the KNN graph using the function 'makeNhoods' 1038 (prop=0.1, k=30, d=30). The number of cells belonging to each sample in each neighbourhood 1039 was counted using the function 'countCells'. We included 'time from infection' in the design 1040 to account for the length of disease. SpatialFDR < 0.1 was used as a cut off point for significant 1041 enrichment/depletion.

1042

1043 BCR and TCR data processing

1044

Single-cell BCR and TCR data were initially processed with cellranger-vdj (v.6.0.0). Single cell
 TCR data was then converted into a cell by TCR format using scirpy v1.10.1 ⁴⁹. BCR contigs
 contained in all contigs.fasta and all contig annotations.csv were then processed further

using *dandelion⁵⁰* singularity container (v.0.2.4) (https://www.github.com/zktuong/dandelion).
BCRs were then matched to cell barcodes with *dandelion*.

1050

1051 TCR analysis

After quality control, we recovered 197,330 T cells with fully resolved T cell receptors from 61 1052 1053 donors and across 187 samples. We identified 127,670 unique TCR clones, defined by a 1054 unique combination of CDR3a, TRAV, TRAJ, CDR3B, TRBV, TRBJ and donor, at the amino 1055 acid level. Of these, 93,960 came from COVID-19 positive ESKD patients and thus could be 1056 analysed longitudinally over the course of infection. A total of 3,727 clones (4%) were captured 1057 at two or more time points during infection. We further excluded all clones present in pre-1058 pandemic samples for analysis related to COVID-19, as these could not have expanded in response to SARS-CoV-2, and finally obtained 3,137 clones (3.3%) for longitudinal analysis. 1059 1060 Clonal frequency within a sample was calculated as total number of clone copies per sample 1061 over the total number of T cells within the sample. To determine expansion, only clones that 1062 were sampled at two time points or more within the 0 to 30 days after a positive PCR nasal swab, and that were absent in the pre-COVID-19 samples, were used. An expansion was 1063 1064 noted if the highest clone frequency measured before a specific day since positive swab 1065 (cutoff) was lower than the lowest frequency measured after that day. If the clone was not 1066 sampled either before or after the cutoff, the respective frequency was set to 0. The cutoff at 1067 day 10 was selected as being in agreement with timing of an adaptive immune response. For 1068 the more stringent definition of expansion as determined by a dual cutoff, the clone frequency 1069 had to show an increase at the first cutoff and a further increase at the second cutoff. This 1070 allowed the capture of a steeper increase of clonal frequency over time, at the cost of 1071 considering fewer total clones.

1072

1073 SARS-CoV-2 specific TCR-epitope pairs were queried from VDJDB. Samples from before the 1074 pandemic were used to establish a baseline of matches with the database. While a single-1075 chain match with the database only indicates a putatively binding TCR, quantifying significant 1076 differences in these numbers across T cell populations gives insight into antigen-specificity. 1077 Matches with the database were quantified for expanding and non-expanding clones using 1078 bar charts, where the error bars show variation across individual COVID-19 patients, and 1079 significance was determined with a two-sided Mann-Whitney test. To determine which clones 1080 were expanding the most, expansion was determined as the mean clonal frequency after the 1081 cutoff day divided by the mean clonal frequency before and sorted in descending order. 1082

Activated T cells were identified by applying the automatic cell type classifier Celltypist (1.2.0,
 model = COVID19_HumanChallenge_Blood) and sub-setting to activated T cells.

1085

1086 Cell2TCR (0.1) was used on the clones that showed expansion according to the above
1087 definition using days 2 and 10 as dual cutoffs, and to generate TCR motifs, while excluding
1088 TCR sequences of MAI T cells.

1089

1090 TCR analyses were carried out in Python (3.10.2) using pandas (1.4.2), numpy (1.21.6) and 1091 scanpy (1.9.1), and visualised with matplotlib (3.5.2) and seaborn (0.11.2), in particular 1092 seaborn's lineplot to show clonal frequency evolution. Statistical tests were carried out using 1093 the scipy.stats module (1.8.1) and plotted with statannotations (0.5.0). The regression line and 1094 R2 value were determined with the seaborn's regplot function.

1095

1096 References

1097 1. Williamson, E. J. et al. Factors associated with COVID-19-related death using

1098 OpenSAFELY. *Nature* **584**, 430–436 (2020).

- 1099 2. Schurink, B. et al. Viral presence and immunopathology in patients with lethal COVID-
- 1100 19: a prospective autopsy cohort study. *Lancet Microbe* **1**, e290–e299 (2020).
- 1101 3. RECOVERY Collaborative Group et al. Dexamethasone in Hospitalized Patients with
- 1102 Covid-19. N. Engl. J. Med. **384**, 693–704 (2021).
- 1103 4. REMAP-CAP Investigators *et al.* Interleukin-6 Receptor Antagonists in Critically III
- 1104 Patients with Covid-19. *N. Engl. J. Med.* **384**, 1491–1502 (2021).
- 1105 5. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with
- 1106 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*
- **397**, 1637–1645 (2021).
- Huang, J., Zhou, C., Deng, J. & Zhou, J. JAK inhibition as a new treatment strategy for
 patients with COVID-19. *Biochem. Pharmacol.* **202**, 115162 (2022).
- 1110 7. Zoccali, C. *et al.* The systemic nature of CKD. *Nat. Rev. Nephrol.* **13**, 344–358 (2017).
- 1111 8. Sarnak, M. J. & Jaber, B. L. Mortality caused by sepsis in patients with end-stage renal
 1112 disease compared with the general population. *Kidney Int.* 58, 1758–1764 (2000).
- 1113 9. Domínguez Conde, C. *et al.* Cross-tissue immune cell analysis reveals tissue-specific
 1114 features in humans. *Science* 376, eabl5197 (2022).
- 1115 10. Stephenson, E. *et al.* Single-cell multi-omics analysis of the immune response in
 1116 COVID-19. *Nat. Med.* 27, 904–916 (2021).
- 1117 11. Yoshida, M. *et al.* Local and systemic responses to SARS-CoV-2 infection in children
- 1118 and adults. *Nature* **602**, 321–327 (2022).
- 1119 12. Chan, K. R. *et al.* Early peripheral blood MCEMP1 and HLA-DRA expression predicts
- 1120 COVID-19 prognosis. *EBioMedicine* **89**, 104472 (2023).
- 1121 13. Mann, E. R. *et al.* Longitudinal immune profiling reveals key myeloid signatures
- associated with COVID-19. Sci Immunol 5, (2020).
- 1123 14. Gisby, J. et al. Longitudinal proteomic profiling of dialysis patients with COVID-19

- reveals markers of severity and predictors of death. *Elife* **10**, (2021).
- 1125 15. Filbin, M. R. et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-
- associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep Med*

1127 2, 100287 (2021).

- 1128 16. Ugalde, A. P. et al. Autophagy-linked plasma and lysosomal membrane protein PLAC8
- is a key host factor for SARS-CoV-2 entry into human cells. *EMBO J.* **41**, e110727
- 1130 (2022).
- 1131 17. Thwaites, R. S. *et al.* Inflammatory profiles across the spectrum of disease reveal a
 distinct role for GM-CSF in severe COVID-19. *Sci Immunol* 6, (2021).
- 1133 18. Goncharov, M. et al. VDJdb in the pandemic era: a compendium of T cell receptors
- 1134 specific for SARS-CoV-2. *Nat. Methods* **19**, 1017–1019 (2022).
- 1135 19. Lindeboom, R. G. H. *et al.* Human SARS-CoV-2 challenge resolves local and systemic
 1136 response dynamics. *bioRxiv* (2023) doi:10.1101/2023.04.13.23288227.
- 1137 20. Coutinho, A. E. & Chapman, K. E. The anti-inflammatory and immunosuppressive
- 1138 effects of glucocorticoids, recent developments and mechanistic insights. *Mol. Cell.*
- 1139 *Endocrinol.* **335**, 2–13 (2011).
- 1140 21. Ehrchen, J. M., Roth, J. & Barczyk-Kahlert, K. More Than Suppression: Glucocorticoid
- 1141 Action on Monocytes and Macrophages. *Front. Immunol.* **10**, 2028 (2019).
- 1142 22. Ehrchen, J. et al. Glucocorticoids induce differentiation of a specifically activated, anti-
- inflammatory subtype of human monocytes. *Blood* **109**, 1265–1274 (2007).
- 1144 23. Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D. & Marioni, J. C.
- 1145 Differential abundance testing on single-cell data using k-nearest neighbor graphs. *Nat.*
- 1146 Biotechnol. **40**, 245–253 (2022).
- 1147 24. Skytthe, M. K., Graversen, J. H. & Moestrup, S. K. Targeting of CD163 Macrophages in
 1148 Inflammatory and Malignant Diseases. *Int. J. Mol. Sci.* 21, (2020).
- 1149 25. Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation.
- 1150 Nat. Rev. Immunol. **8**, 958–969 (2008).
- 1151 26. Qu, R. et al. Glucocorticoids improve the balance of M1/M2 macrophage polarization in

- 1152 experimental autoimmune uveitis through the P38MAPK-MEF2C axis. Int.
- 1153 *Immunopharmacol.* **120**, 110392 (2023).
- 1154 27. Xue, J. et al. Transcriptome-based network analysis reveals a spectrum model of
- 1155 human macrophage activation. *Immunity* **40**, 274–288 (2014).
- 1156 28. Ogawa, Y. *et al.* Peripherally administered orexin improves survival of mice with
- 1157 endotoxin shock. *Elife* **5**, (2016).
- 1158 29. Becquet, L. et al. Systemic administration of orexin A ameliorates established
- 1159 experimental autoimmune encephalomyelitis by diminishing neuroinflammation. J.
- 1160 *Neuroinflammation* **16**, 64 (2019).
- 1161 30. Tse, L. V. et al. Genomewide CRISPR knockout screen identified PLAC8 as an
- 1162 essential factor for SADS-CoVs infection. *Proc. Natl. Acad. Sci. U. S. A.* **119**,
- 1163 e2118126119 (2022).
- 1164 31. Ren, X. *et al.* COVID-19 immune features revealed by a large-scale single-cell
 1165 transcriptome atlas. *Cell* **184**, 1895–1913.e19 (2021).
- 1166 32. Zhao, J. H. et al. Genetics of circulating inflammatory proteins identifies drivers of
- 1167 immune-mediated disease risk and therapeutic targets. *Nat. Immunol.* 24, 1540–1551
 1168 (2023).
- 1169 33. Kokkotis, G. et al. Systematic review with meta-analysis: COVID-19 outcomes in
- 1170 patients receiving anti-TNF treatments. *Aliment. Pharmacol. Ther.* **55**, 154–167 (2022).
- 1171 34. Khan, S. F. & Bowman, B. T. Vaccinating the Patient with ESKD. *Clin. J. Am. Soc.*
- 1172 Nephrol. 14, 1525–1527 (2019).
- 1173 35. Carr, E. J. et al. Neutralising antibodies after COVID-19 vaccination in UK
- haemodialysis patients. *The Lancet* vol. 398 1038–1041 (2021).
- 1175 36. Carr, E. J. et al. Omicron neutralising antibodies after COVID-19 vaccination in
- 1176 haemodialysis patients. *The Lancet* vol. 399 800–802 (2022).
- 1177 37. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
- 1178 transcriptomic data across different conditions, technologies, and species. *Nat.*
- 1179 *Biotechnol.* **36**, 411–420 (2018).

- 1180 38. Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-
- 1181 based single-cell RNA sequencing data. *Gigascience* **9**, (2020).
- 1182 39. Heaton, H. et al. Souporcell: robust clustering of single-cell RNA-seq data by genotype
- 1183 without reference genotypes. *Nat. Methods* **17**, 615–620 (2020).
- 1184 40. McCarthy, D. J. et al. Cardelino: computational integration of somatic clonal
- substructure and single-cell transcriptomes. *Nat. Methods* **17**, 414–421 (2020).
- 1186 41. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression
- 1187 data analysis. *Genome Biol.* **19**, 15 (2018).
- 1188 42. Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with
- 1189 Harmony. *Nat. Methods* **16**, 1289–1296 (2019).
- 1190 43. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well1191 connected communities. *Sci. Rep.* 9, 5233 (2019).
- 44. Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. & Yosef, N. Deep generative modeling
 for single-cell transcriptomics. *Nat. Methods* 15, 1053–1058 (2018).
- 1194 45. Monaco, G. et al. RNA-Seq Signatures Normalized by mRNA Abundance Allow
- Absolute Deconvolution of Human Immune Cell Types. *Cell Rep.* 26, 1627–1640.e7
 (2019).
- 1197 46. Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set
 1198 collection. *Cell Syst* 1, 417–425 (2015).
- 47. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and
 powerful approach to multiple testing. *J. R. Stat. Soc.* 57, 289–300 (1995).
- 1201 48. Lê, S., Josse, J. & Husson, F. FactoMineR: An R Package for Multivariate Analysis. *J.*
- 1202 Stat. Softw. **25**, 1–18 (2008).
- 49. Sturm, G. *et al.* Scirpy: a Scanpy extension for analyzing single-cell T-cell receptorsequencing data. *Bioinformatics* 36, 4817–4818 (2020).
- 1205 50. Suo, C. et al. Dandelion uses the single-cell adaptive immune receptor repertoire to
- 1206 explore lymphocyte developmental origins. *Nat. Biotechnol.* **42**, 40–51 (2024).

















1.0

0.5 0.0

-0.5

-1.0

60

С











> mild_moderate severe_critical

3





С



d







Day from steroid

